

Additional file 4. Pulmonary microbiological findings in patients with isolated pulmonary *Candida spp.* colonization during observation period (cohort 1).

	Antifungal therapy (n=102)	No antifungal therapy (n=220)	p-value
<i>Candida spp.</i>, n (%)			
<i>albicans</i>	78 (76.5%)	183 (83.2%)	0.17
<i>glabrata</i>	31 (30.4%)	42 (19.1%)	0.031
<i>tropicalis</i>	16 (15.7%)	18 (8.2%)	0.051
<i>krusei</i>	6 (5.9%)	1 (0.5%)	0.005
Others ¹	15 (14.7%)	23 (10.5%)	0.271
Co-Infection with <i>Aspergillus</i> , n (%)	2 (2%)	3 (1.4%)	0.654
Any new pulmonary bacterial finding, n (%)	53 (52%)	120 (55%)	0.719
Gram positive	15 (14.7%)	25 (11.4%)	0.468
Gram negative	48 (47.1%)	107 (48.6%)	0.811
<i>E. Coli</i>	11 (10.8%)	25 (11.4%)	1
<i>Pseudomonas aeruginosa</i>	12 (11.8%)	15 (6.8%)	0.193
<i>Klebsiella pneumonia</i>	8 (7.8%)	14 (13.7%)	0.639
<i>Enterobacter species</i>	8 (7.8%)	13 (5.9%)	0.628
Others ²	9 (8.8%)	40 (18.2%)	0.031
multi drug resistant pathogens	6 (5.9%)	7 (3.2%)	0.36

¹ *Candida famata*, *kefyr*, *lipolytica*, *lusitaniae* and *parapsilosis*.

² *Stenotrophomonas*, *Proteus mirabilis*, *Serratia marcescens*, *Citrobacter koseri*, *Actinobacter baumannii*, *Klebsiella ocytoca*, *Proteus vulgaris*, *Citrobacter freundii*, *Morganella morgannii*, *Burkholderia cepacia*.